Cellectar Biosciences Inc.

News & Events

Press Releases

In The Media

1. Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

   GlobeNewswire AUG 14, 2025 7:19 AM EDT
   Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofos...
   READ ARTICLE

2. Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

   GlobeNewswire AUG 7, 2025 8:05 AM EDT
   FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB),...
   READ ARTICLE

3. Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

   GlobeNewswire JUL 2, 2025 4:15 PM EDT
   FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ...
   READ ARTICLE

4. Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

   GlobeNewswire JUL 1, 2025 9:25 AM EDT
   FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ...
   READ ARTICLE

5. Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

   Canada Newswire JUN 30, 2025 11:02 AM EDT
   Oncology Innovation Just Hit a Turning Point -- Here's What to Watch Canada NewsWire ...
   READ ARTICLE

6. Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

   PR Newswire JUN 30, 2025 11:02 AM EDT
   Oncology Innovation Just Hit a Turning Point -- Here's What to Watch PR Newswire ...
   READ ARTICLE

7. Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

   GlobeNewswire JUN 26, 2025 8:05 AM EDT
   Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement...
   READ ARTICLE

8. Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

   GlobeNewswire JUN 24, 2025 8:30 AM EDT
   Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitt...
   READ ARTICLE

9. Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

   GlobeNewswire JUN 18, 2025 4:30 PM EDT
   FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB),...
   READ ARTICLE

10. Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

    GlobeNewswire JUN 11, 2025 8:05 AM EDT
    FLORHAM PARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB),...
    READ ARTICLE